Author

Suman Sen

Observed name: Sen, Suman

Observed institutions: Fox Chase Cancer Center, Novartis (United States), Duke Medical Center, Tennessee Oncology, UNC Lineberger Comprehensive Cancer Center

OpenAlex ID: A5003756097

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

2014 · Jeffrey R. Infante, E. Claire Dees, et al. · Journal of Clinical Oncology · 208

CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo

2006 · Karen M Haas, Suman Sen, et al. · The Journal of Immunology · 73

Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects

2013 · Shyeilla Dhuria, Heidi Einolf, et al. · The Journal of Clinical Pharmacology · 23

Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials

2022 · Rong Liu, Ying Yuan, et al. · Statistics in Biopharmaceutical Research · 11

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

2023 · Olga Marchenko, Rajeshwari Sridhara, et al. · Statistics in Biopharmaceutical Research · 4

Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective

2024 · Rong Liu, Ying Yuan, et al. · Statistics in Biopharmaceutical Research · 3

Retrospective Evaluation of Switching from Aflibercept to Biosimilar Ranibizumab: A Multicenter Real-world Study

2026 · Debdulal Chakraborty, Tushar Kanti Sinha, et al. · Journal of Ophthalmological Society of West Bengal

Works count: 9

Citation count: 322

H-index: 4

I10-index: 4